sorafenib has been researched along with Diabetes Mellitus in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Abo Elseud, Y; Albarrak, J; Mohanty, A; Salamah, R; Shaaban, A | 1 |
| Dave, V; Gupta, C; Sharma, R; Sur, S | 1 |
| Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY | 1 |
| Bardin, C; Blanchet, B; Desbois-Mouthon, C; Hamoudi, RA; Harati, R; Praz, F; Vandamme, M | 1 |
| Burkemper, NM; Chappell, JA; Semchyshyn, N | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Ciampi Dopazo, JJ; de Artaza Varasa, T; de la Cruz Perez, G; Gómez Moreno, AZ; Gómez Rodríguez, R; González de Frutos, C; Lanciego Pérez, C; Romero Gutiérrez, M | 1 |
| Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C | 1 |
9 other study(ies) available for sorafenib and Diabetes Mellitus
| Article | Year |
|---|---|
Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Diabetes Mellitus; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Obesity; Platelet Count; Prevalence; Prognosis; Proportional Hazards Models; Radiotherapy; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Rate | 2020 |
Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Kuwait; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Sorafenib; Treatment Outcome | 2021 |
Folic acid modified gold nanoparticle for targeted delivery of Sorafenib tosylate towards the treatment of diabetic retinopathy.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Delivery Systems; Folic Acid; Gold; Humans; Metal Nanoparticles; Sorafenib | 2020 |
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Taiwan | 2020 |
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diabetes Mellitus; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hep G2 Cells; Humans; Liver Neoplasms; Metformin; Mice; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Localized dyskeratotic plaque with milia associated with sorafenib.
Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Early Detection of Cancer; Ethanol; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sclerotherapy; Sorafenib; Spain | 2011 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Humans; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |